If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 141 - 150 of 289
A Phase 1b Trial of Ivosidenib Combined with Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs
Objective
This project is being done to learn about the safety of combining the JAK inhibitor
ruxolitinib with the IDH1 inhibitor ivosidenib in IDH1-mutated, advanced-phase, Ph-negative myeloproliferative neoplasms.
ruxolitinib with the IDH1 inhibitor ivosidenib in IDH1-mutated, advanced-phase, Ph-negative myeloproliferative neoplasms.
Protocol No
UCHICAGO-IRB23-1681
Categories
Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
Objective
Study of teclistamab combined with lenalidomide for newly diagnosed multiple myeloma patients
Protocol No
EMN30-64007957MMY3003-MAJESTEC
Categories
A Randomized Phase III Trial Evaluating the Safety and Efficacy of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant and Adjuvant Chemotherapy in Newly Diagn
Objective
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer (OVATION-3)
Protocol No
IMUNON-IMNN-001-OVATION-3
Categories
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
Objective
Study comparing new treatments for newly diagnosed AML with IDH2 gene change
Protocol No
SWOG-MM1OA-S03
Categories
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Objective
Study of IMVT-1402 Treatment in Adult Participants with CIDP
Protocol No
NEURO-IMVT-1402-2401
Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy DMT to Ublituximab -ENHANCE
Objective
Efficacy Transitioning from a Current DMT to Ublituximab
Protocol No
NEURO-TG-ENHANCE
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Objective
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in
Advanced KRAS Mutated Cholangiocarcinoma
Advanced KRAS Mutated Cholangiocarcinoma
Protocol No
GENFIT-GNS561-222-1
Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged
Objective
A Phase III study comparing the use investigational drug ziftomenib to intensive chemotherapy and and the use of ziftomenib as maintenance therapy following intensive chemotherapy.
Protocol No
KURA-KO-MEN-017
Categories
Frontline T-Cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification Therapy in Multiple Myeloma
Objective
Study of t-cell engager vs. stem cell transplant and MRD-guided therapy in multiple myeloma
Protocol No
SCRI-FASTER-MM195
Categories
A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of
Paltusotine in Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors
Objective
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Protocol No
CRINETICS-CRN00808-12